Literature DB >> 21928725

The PK/PD index (CMAX/MIC) for ciprofloxacin in patients with cystic fibrosis.

Edyta Szałek1, Agnieszka Kamińska, Joanna Gozdzik-Spychalska, Edmund Grześkowiak, Halina Batura-Gabryel.   

Abstract

In order to evaluate the efficacy of an antibacterial therapy, three basic PK/PD indexes were defined: the ratio between the maximum drug concentration obtained after a single dose and minimum inhibitory concentration MIC (CMAX/MIC), the ratio between the area under the curve of dependence between the drug concentration in blood and time within 24 hours to MIC (AUC24/MIC), and the time when the concentration of the drug in blood is higher than MIC (T > MIC). The aim of the study was an analysis of the pharmacokinetics of ciprofloxacin and the PK/PD: CMAX/MIC index in patients with cystic fibrosis. Six patients with cystic fibrosis, with the identified microbiological factor were subjected to the examination. The patients received ciprofloxacin in the dose of 400 mg/12 h (i.v.). Plasma drug concentration was measured by HPLC-UV method after the first dose (Cmax1) and at steady state (Cssmax, Cssmin). The following mean values of ciprofloxacin blood concentrations were obtained from the analyzed patients: Cmax1 = 2.34 (+/- 1.15) microg/mL, Cssmax = 2.49 (+/- 1.44) pg/mL, Cssmin = 0.42 (+/- 0.22) pg/mL. The mean values of the Cmax1/MIC and Cssmax/MIC indexes were 3.66 +/- 2.34) and 3.38 (+/-1.73), respectively. Low values of the Cmax/MIC index for ciprofloxacin in the analyzed patients may indicate too low concentrations of the drug in the blood in relation to the MIC value of pathogens and the need to verify the assumed administration scheme.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21928725

Source DB:  PubMed          Journal:  Acta Pol Pharm        ISSN: 0001-6837            Impact factor:   0.330


  5 in total

Review 1.  Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors:  Axel Dalhoff
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

2.  Gene Polymorphism of Biotransformation Enzymes and Ciprofloxacin Pharmacokinetics in Pediatric Patients with Cystic Fibrosis.

Authors:  Sergey K Zyryanov; Elena A Ushkalova; Elena I Kondratyeva; Olga I Butranova; Yulia A Kondakova
Journal:  Biomedicines       Date:  2022-05-02

3.  Pseudomonas aeruginosa exoproducts determine antibiotic efficacy against Staphylococcus aureus.

Authors:  Lauren Radlinski; Sarah E Rowe; Laurel B Kartchner; Robert Maile; Bruce A Cairns; Nicholas P Vitko; Cindy J Gode; Anne M Lachiewicz; Matthew C Wolfgang; Brian P Conlon
Journal:  PLoS Biol       Date:  2017-11-27       Impact factor: 8.029

4.  Reactive oxygen species induce antibiotic tolerance during systemic Staphylococcus aureus infection.

Authors:  Sarah E Rowe; Nikki J Wagner; Lupeng Li; Jenna E Beam; Alec D Wilkinson; Lauren C Radlinski; Qing Zhang; Edward A Miao; Brian P Conlon
Journal:  Nat Microbiol       Date:  2019-12-09       Impact factor: 17.745

5.  Effects of berberine and hwangryunhaedok-tang on oral bioavailability and pharmacokinetics of ciprofloxacin in rats.

Authors:  Youn-Hwan Hwang; Won-Kyung Cho; Doorye Jang; Jeong-Ho Ha; Kiyoun Jung; Hyo-In Yun; Jin Yeul Ma
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-24       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.